The U.S. Food and Drug Administration (FDA) approved Eli Lilly’s Inluriyo-Verzenio combination for specific advanced breast cancers. The treatment targets adults with HR-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. This approval applies to patients whose disease progressed after at least one hormone-based therapy.
A late-stage study demonstrated that the combination significantly improved progression-free survival. Patients receiving the combination went a median of 11.1 months before their cancer worsened. Patients taking Inluriyo alone reached a median of 5.5 months.
HR+/HER2- is the most common breast cancer subtype. Inluriyo is a daily pill that blocks and degrades estrogen receptors. Verzenio is a twice-daily pill that inhibits cancer-cell division. Eli Lilly made the therapy available immediately in the United States.